Financhill
Back

BeiGene 10K Form

Sell
35

BGNE
BeiGene

Last Price:
207.51
Seasonality Move:
13.54%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive BGNE News And Ratings

See the #1 stock for the next 7 days that we like better than BGNE

BGNE Financial Statistics

Sales & Book Value

Annual Sales: $2.46B
Cash Flow: $-205.54M
Price / Cash Flow: 0
Annual Sales: $31.81
Price / Book: 6.44

Profitability

EPS (TTM): -5.20000
Net Income (TTM): $-523.7M
Gross Margin: $2.08B
Return on Equity: -14.69%
Return on Assets: -9.21%

BeiGene Earnings Forecast

Key BeiGene Financial Ratios

  • The Gross Profit Margin over the past 11 years for BGNE is 84.55%.
  • The Selling, General & Administrative Expenses for BGNE have been equal to 61.19% of Gross Profit Margin.
  • The Research & Development expenses have been 72.34% of Revenue.
  • The Interest Expense is -42.19% of Operating Income.
  • The Net Earning history of BGNE is -35.86% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 3 years.

BeiGene Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: BGNE
CUSIP: 07725L
Website: beigene.com

Debt

Debt-to-Equity Ratio: 0.31
Current Ratio: 1.98
Quick Ratio: 1.64

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BGNE Technical Analysis vs Fundamental Analysis

Sell
35
BeiGene (BGNE) is a Sell

Is BeiGene a Buy or a Sell?

  • BeiGene stock is rated a Sell
    The current BeiGene [BGNE] share price is $204.21. The Score for BGNE is 35, which is 30% below its historic median score of 50, and infers higher risk than normal.